Advanced Enzyme Technologies
- Market cap
- ₹ 2,779 Cr.
- P/E
- 18.5x
- P/B
- 1.76x
- 52-week range
- 246.8 – 419
- ROE
- 10%
- ROCE
- 14%
- Dividend yield
- 0.5%
- Debt / equity
- 0.02
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Biotechnology
- Listed on
- NSE, BSE
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Biotechnology: 6 companies →Advanced Enzyme Technologies against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)18.5 against a typical 64.5: cheaper than most peers (1st = cheapest).2nd of 6
- Sales growth+2.2% against a typical +2.2% from a year earlier.3rd of 5
- Profit growth−2.5% against a typical −50% from a year earlier.1st of 5
- Share price, 3 months−15.7% against a typical −13.2%.4th of 5
- Size₹ 2,779.3 Cr. market value against a typical ₹ 82.4 Cr. (1st = largest).2nd of 6
Latest announcements
Exchange filings and their impact on the company.
- Extinguished 0.89m buyback shares in September, taking total to 1.71m (~1.5% of capital) - small EPS-accretive buyback.
Advanced Enzyme Technologies extinguished 888,296 shares bought back in September 2026 under its ongoing open-market buyback announced on August 10, 2026. Total shares extinguished so far are 1,713,324, reducing paid-up capital to 110,262,826 shares of Rs 2 each. At current prices this implies a cash outflow of around Rs 47 crore, a small ~1.5% capital reduction that is slightly EPS-accretive.
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Adequate safety
Rated AA- to A+ by 2 agencies- All agencies agree and none has raised a warning.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CRISIL | Crisil A+ | Stable | 30 Apr 2026 |
| ICRA | [ICRA]AA- /[ICRA]A1+ | Stable | 13 Feb 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 30 Apr 2026 | Reaffirmed | Crisil A+ | — | CRISIL | ₹ 100 Cr. | |
| 13 Feb 2026 | New rating | [ICRA]AA- /[ICRA]A1+ | — | ICRA | ₹ 100 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 31 Oct 2026Upcoming | Financial Results | To consider and approve the financial results for the period ended September 30, 2026 |
| 8 Aug 2026 | Buyback | To consider buyback for equity shares |
| 9 May 2026 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2026 and dividend |
| 31 Jan 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 12 Nov 2025 | Financial Results | This is to inform that the Meeting of Board of Directors of the Company is scheduled to be held on Wednesday, November 12, 2025, inter alia, to consider and approve Un-audited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2025 |
| 2 Aug 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
| 13 May 2025 | Financial Results/Dividend | Intimation of Board Meeting, Record date for interim dividend, if declared by the Board andclosure of Trading Window |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 158 | 161 | 158 | 155 | 146 | 169 | 167 | 186 | 185 | 172 | 203 | 190 |
| Expenses | 107 | 107 | 102 | 103 | 104 | 114 | 122 | 129 | 124 | 123 | 140 | 139 |
| Operating Profit | 51 | 54 | 55 | 51 | 42 | 55 | 46 | 56 | 60 | 49 | 63 | 51 |
| OPM % | 32% | 33% | 35% | 33% | 29% | 33% | 27% | 30% | 33% | 29% | 31% | 27% |
| Other Income | 6 | 14 | −6 | 7 | 10 | 8 | 9 | 9 | 10 | 20 | 7 | 13 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 9 | 9 | 9 | 9 | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 10 |
| Profit before tax | 48 | 59 | 40 | 49 | 42 | 53 | 43 | 55 | 60 | 58 | 60 | 54 |
| Tax % | 27% | 28% | 25% | 28% | 21% | 27% | 38% | 26% | 25% | 26% | 24% | 28% |
| Net Profit | 35 | 42 | 30 | 35 | 33 | 39 | 27 | 40 | 45 | 43 | 45 | 39 |
| EPS in Rs | 3.08 | 3.74 | 2.53 | 3.05 | 2.94 | 3.37 | 2.37 | 3.57 | 3.87 | 3.8 | 3.84 | 3.31 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 10%
- 5 Years
- 8%
- 3 Years
- 11%
- TTM
- 12%
- 10 Years
- 7%
- 5 Years
- 1%
- 3 Years
- 12%
- TTM
- 15%
- 10 Years
- 1%
- 5 Years
- −4%
- 3 Years
- −2%
- TTM
- —
- 10 Years
- 13%
- 5 Years
- 10%
- 3 Years
- 10%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Prices are delayed and for information only. Nothing on this page is investment advice.